AbbVie oncology research across seven assets will feature at the European Society for Medical Oncology Congress in Madrid on October 23–27, 2026. Announcing the program on October 18, the company described it as its largest ESMO presence yet, with updates covering lung, colorectal, ovarian, prostate and gastric cancers.
Key Takeaways
- The program includes investigational treatments and approved medicines across five cancer types.
- Temab-A and ABBV-706 updates include early-stage response and survival findings alongside ongoing Phase 3 trials.
- The presentations are research updates, not new regulatory approvals or evidence of commercial revenue.
Table of Contents
- AbbVie oncology program broadens its solid-tumor focus
- Temab-A updates cover colorectal and lung cancer
- Other assets add response, biomarker and safety findings
- Presentation schedule and approval status remain distinct
- Conclusion
AbbVie oncology program broadens its solid-tumor focus
AbbVie’s ESMO 2026 presentation announcement outlines research on Temab-A, ABBV-706, ABBV-969, ABBV-1480, alveltamig, Emrelis and Elahere. The program spans antibody-drug conjugates, which pair targeted antibodies with drug payloads, as well as other antibody-based approaches and combination treatments.
For the company’s development pipeline, the distinction is between promising early findings and confirmation in larger trials. Several highlighted results come from Phase 1 studies, while follow-on Phase 3 programs remain underway.
| Item | Details |
|---|---|
| October 23, 2026 | ABBV-969 prostate-cancer biomarker poster. |
| October 24, 2026 | Temab-A lung- and colorectal-cancer survival presentations. |
| October 25, 2026 | ABBV-1480 combination findings in gastric or gastroesophageal junction cancer. |
| October 26, 2026 | ABBV-706, alveltamig, Emrelis, Elahere and additional Temab-A and ABBV-1480 presentations. |
Temab-A updates cover colorectal and lung cancer
In previously treated advanced colorectal cancer, AbbVie reported a 30% overall response rate for Temab-A combined with bevacizumab at the 2.4 mg/kg dose. After median follow-up of 18.2 months, median overall survival was 14.7 months in the combination group of 30 patients, compared with 10.2 months among 20 patients receiving standard care.
These are Phase 1 findings from small patient groups, rather than confirmatory Phase 3 results. AbbVie said no new safety signals were observed, and the combination is being evaluated further in the global Phase 3 AndroMETa-CRC-560 study.
Updated Phase 1 lung-cancer findings showed a 50% response rate and median overall survival of 13.8 months among 48 patients with EGFR wild-type disease. Among 41 patients with EGFR-mutant disease, the response rate was 63% and median overall survival was 16.2 months. A separate Phase 3 trial is evaluating Temab-A against standard care in previously treated EGFR wild-type, non-squamous non-small cell lung cancer.
Other assets add response, biomarker and safety findings
For ABBV-706, updated Phase 1 data at the selected Phase 3 dose showed a 56% response rate and median overall survival of 12.4 months in 41 patients with small cell lung cancer receiving second-line or later treatment. AbbVie said safety was comparable with previously reported data; a randomized Phase 3 comparison with standard care is ongoing.
ABBV-969 presentations focus on biomarker findings in heavily pretreated metastatic castration-resistant prostate cancer. ABBV-1480 updates include lung-cancer monotherapy and combination results, with continued Phase 3 development and a newly initiated combination study with Temab-A.
Safety remains part of that assessment. For ABBV-1480 monotherapy, the most common grade 3 or higher treatment-related adverse events were hypertension and proteinuria. With docetaxel, they included reduced neutrophil, white blood cell and lymphocyte counts.
Presentation schedule and approval status remain distinct
The congress program also includes Elahere ovarian-cancer analyses, real-world Emrelis use and updated alveltamig survival findings. These studies involve different populations and designs, so their results should not be treated as direct comparisons between medicines.
Temab-A, ABBV-706 and ABBV-969 are investigational and are not approved by any health authority worldwide; their safety and efficacy have not been established. ABBV-1480 and alveltamig also remain investigational. Presentations involving approved medicines do not themselves establish approval for the combinations or patient groups being studied.
Conclusion
The next confirmed milestones are the scheduled ESMO presentations on October 23–27. They will provide further detail on the disclosed findings, while ongoing Phase 3 studies remain separate tests of the investigational treatments.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
